Preoperative Serum Human Epididymis Protein 4 Levels in Early Stage Endometrial Cancer: A Prospective Study
- PMID: 28557834
- DOI: 10.1097/IGC.0000000000001015
Preoperative Serum Human Epididymis Protein 4 Levels in Early Stage Endometrial Cancer: A Prospective Study
Abstract
Objective: The aim of the study was to evaluate the prognostic value of human epididymis protein 4 (HE4) and cancer antigen 125 markers with pathological prognostic factor to complete the preoperative clinical panel and help the treatment planning.
Methods: This prospective multicenter study was conducted in 2 gynecologic oncology centers between 2012 and 2014 (Institute for Maternal and Child Health IRCCS Burlo Garofolo in Trieste and Catholic University of the Sacred Heart in Rome, Italy). We enrolled 153 patients diagnosed with clinical early (International Federation of Gynecology and Obstetrics stages I-II) type I endometrial cancer.
Results: Human epididymis protein 4 levels seemed to be strictly related to age (P < 0.001) and menopausal status (P < 0.002). Compared with myometrial invasion (MI), the HE4 values were significantly higher in case of invasion of greater than 50% of the thickness: MI of greater than 50%, median of 94.85 pmol/L (38.3-820.8 pmol/L), versus MI of less than 50%, median of 65.65 pmol/L (25.1-360.2 pmol/L), (P < 0.001). The HE4 levels increase significantly with increasing tumor size: diameter of larger than 2 cm, median of 86.9 pmol/L (35.8-820.8 pmol/L), versus diameter of smaller than 2 cm, median of 52.2 pmol/L (33.3-146.8 pmol/L), (P < 0.001). In our population, HE4 did not correlate with the histological grade, endometrial cancer type I versus type II (P = 0.86), the lymphovascular infiltration (P = 0.12), and the cervical invasion (P = 0.6). We established a new variable, considering 3 high-risk tumor features: MI of greater than 50% and/or histological G3 and/or type II. Human epididymis protein 4 levels significantly increase in high-risk tumors (high risk HE4, 93.6 pmol/L vs low-medium risk, 65.5 pmol/L; P < 0.001).
Conclusions: A preoperative HE4 evaluation could help stratify patients with deep invasion and/or metastatic disease and is correlated with other relevant prognostic factors to be considered to tailor an adequate surgical strategy.
Similar articles
-
Human Epididymis Protein 4 Predicted Concurrent Intermediate-high-risk Endometrial Cancer and Eligibility of Fertility-sparing Treatment for Patients Diagnosed with Endometrial Atypical Hyperplasia Before Surgery.Int J Med Sci. 2025 Jul 11;22(13):3292-3303. doi: 10.7150/ijms.115170. eCollection 2025. Int J Med Sci. 2025. PMID: 40765568 Free PMC article.
-
Preoperative Magnetic Resonance Volumetry in Predicting Myometrial Invasion, Lymphovascular Space Invasion, and Tumor Grade: Is It Valuable in International Federation of Gynecology and Obstetrics Stage I Endometrial Cancer?Int J Gynecol Cancer. 2018 May;28(4):666-674. doi: 10.1097/IGC.0000000000001208. Int J Gynecol Cancer. 2018. PMID: 29697491
-
Prognostic values of human epididymis protein 4 expression in patients with endometrial cancer: A systematic review and meta-analysis.J Obstet Gynaecol Res. 2022 Sep;48(9):2255-2269. doi: 10.1111/jog.15356. Epub 2022 Jul 17. J Obstet Gynaecol Res. 2022. PMID: 35844088
-
Tumor size: a better independent predictor of distant failure and death than depth of myometrial invasion in International Federation of Gynecology and Obstetrics stage I endometrioid endometrial cancer.Int J Gynecol Cancer. 2013 May;23(4):690-7. doi: 10.1097/IGC.0b013e31828c85c6. Int J Gynecol Cancer. 2013. PMID: 23518862
-
Adjuvant radiotherapy for stage I endometrial cancer.Cochrane Database Syst Rev. 2012 Mar 14;(3):CD003916. doi: 10.1002/14651858.CD003916.pub3. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2012 Apr 18;(4):CD003916. doi: 10.1002/14651858.CD003916.pub4. PMID: 22419290 Updated.
Cited by
-
Evaluating pretreatment serum CA-125 levels as prognostic biomarkers in endometrial cancer: a comprehensive meta-analysis.Front Oncol. 2024 Sep 27;14:1442814. doi: 10.3389/fonc.2024.1442814. eCollection 2024. Front Oncol. 2024. PMID: 39399178 Free PMC article. Review.
-
IETA Ultrasonic Features Combined with GI-RADS Classification System and Tumor Biomarkers for Surveillance of Endometrial Carcinoma: An Innovative Study.Cancers (Basel). 2022 Nov 16;14(22):5631. doi: 10.3390/cancers14225631. Cancers (Basel). 2022. PMID: 36428723 Free PMC article.
-
CD44, TGM2 and EpCAM as novel plasma markers in endometrial cancer diagnosis.BMC Cancer. 2019 Apr 29;19(1):401. doi: 10.1186/s12885-019-5556-x. BMC Cancer. 2019. PMID: 31035965 Free PMC article.
-
Combination IETA Ultrasonographic Characteristics Simple Scoring Method With Tumor Biomarkers Effectively Improves the Differentiation Ability of Benign and Malignant Lesions in Endometrium and Uterine Cavity.Front Oncol. 2021 Aug 30;11:605847. doi: 10.3389/fonc.2021.605847. eCollection 2021. Front Oncol. 2021. PMID: 34527571 Free PMC article.
-
Diagnostic and Prognostic Values of Serum EpCAM, TGM2, and HE4 Levels in Endometrial Cancer.Front Oncol. 2020 Sep 4;10:1697. doi: 10.3389/fonc.2020.01697. eCollection 2020. Front Oncol. 2020. PMID: 33014844 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials